VectivBio Holding AG
Aeschenvorstadt 36
4051 Basel, Switzerland
| April 6, 2021 | Via Edgar | ||||
| United States Securities and Exchange Commission | |||||
| Division of Corporation Finance | |||||
| 100 F Street, N.E. | |||||
| Washington, D.C. 20549 | |||||
| Attn: | Ms. Margaret Schwartz | |||||||
Ms. Suzanne Hayes | ||||||||
Ms. Tracie Mariner | ||||||||
Mr. Terence O’Brien | ||||||||
Division of Corporation Finance | ||||||||
Office of Life Sciences | ||||||||
| RE: | VectiveBio Holding AG | |||||||
| Registration Statement on Form F-1 | ||||||||
| File No. 333-254523 | ||||||||
| Acceleration Request | ||||||||
| Requested Date: | April 8, 2021 | |||||||
| Requested Time: | 4:00 P.M. Eastern Time | |||||||
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) to become effective on April 8, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Pascale Lesperance, counsel to the Registrant, at (212) 479-6772.
Very truly yours,
VectivBio Holding AG
/s/ Dr. Luca Santarelli
Dr. Luca Santarelli
Chief Executive Officer
cc: Ryan Sansom, Cooley LLP
Brandon Fenn, Cooley LLP
Pascale Lesperance, Cooley LLP